myelodysplastic syndrome

(redirected from Myelodysplastic syndromes)
Also found in: Medical.
Related to Myelodysplastic syndromes: multiple myeloma, aplastic anemia

myelodysplastic syndrome

n.
Any of a group of disorders characterized by the abnormal proliferation of bone marrow cells that are precursors to blood cells. It is often associated with abnormalities of blood cells such as anemia and leukopenia.
References in periodicals archive ?
a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain.
Opsona Therapeutics Ltd (Opsona), an innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, revealed on Tuesday that it has received orphan drug designation (ODD) from the US Food and Drug Administration for OPN-305 in the rare disease myelodysplastic syndromes (MDS).
Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal haematopoietic disorders characterised by chronic and progressive cytopenias resulting from ineffective haematopoiesis.
The National Institute for Health and Clinical Excellence (Nice) said it has ruled in draft guidance that azacitidine could not be prescribed on the NHS for the treatment of a number of myelodysplastic syndromes (MDS).
Epidemiology classification and prognosis of adults and children with myelodysplastic syndromes.
Primary bone marrow fibrosis is observed in different clonal hematological disorders including chronic myeloproliferative diseases (CMPDs) like chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis and myeloid metaplasia, acute leukemias, especially in AML-M7, and in myelodysplastic syndromes (MDS) [1].
Thus, we think that the myelodysplastic syndromes may be severely underestimated.
Myelodysplastic syndromes are a group of conditions that cause insufficient production of blood cells, which often is lethal.